Aspergillus Immunoassay Denaturation for Diagnostic Reliability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunoassays for diagnosing Aspergillus infections face issues with reproducibility, specificity, and sensitivity, particularly in high-throughput screening, especially for patients with chronic granulomatous disease, hyper-IgE syndrome, and those treated with antifungal drugs, leading to false positives and negatives.
Innovation Solution
A method involving a denaturing step, such as boiling, is applied to serum samples before immunoassay testing using antibodies specific to beta-1,5-galactofuranose, combined with ELISA or bead-based assays, to enhance diagnostic reliability and specificity, employing antibodies like JF5 or variants, which are coated on microplates or beads, to improve sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunoassays are used for detecting Aspergillus galactomannan, then the diagnostic process is simple and rapid, but the reliability, sensitivity and specificity are insufficient leading to false positives and negatives
Solution Approach 1:
The patent applies a denaturing step (boiling) to the serum sample before the immunoassay to prevent protein aggregation and interference. This preliminary treatment improves diagnostic reliability by eliminating false positives and negatives while maintaining assay feasibility through a simple pre-treatment protocol
Solution Approach 2:
The patent changes the physical state of the sample by applying heat (boiling) to denature proteins. This parameter change improves the reliability of antigen detection by preventing aggregation and interference, while the controlled application maintains the overall simplicity of the diagnostic process
2Productivity
If monoclonal antibodies are used for high-throughput screening, then the detection speed increases, but the sensitivity decreases leading to false negatives
Solution Approach 1:
The denaturing step performed before the immunoassay prevents protein aggregation that would otherwise interfere with antibody-antigen binding. This preliminary treatment ensures that even in high-throughput screening where samples are processed rapidly, the sensitivity remains high by eliminating a key source of false negatives
Solution Approach 2:
The patent uses a specific monoclonal antibody (JF5) that recognizes a unique epitope on Aspergillus galactomannan. This intermediary antibody provides both the speed needed for high-throughput screening and the specificity required for sensitive detection, resolving the contradiction between throughput and sensitivity
3Reliability
If standard immunoassay protocols are used without denaturation, then the assay procedure is simple and rapid, but the reproducibility varies significantly
Solution Approach 1:
The denaturing step is performed as a preliminary treatment before the immunoassay to standardize the sample state. This eliminates variability caused by protein aggregation and ensures consistent results across different batches and operators, significantly improving reproducibility
Solution Approach 2:
The patent utilizes the phase transition of water to boiling temperature to denature proteins in the serum sample. This phase change approach is simple to implement, requires minimal additional time, and provides consistent reproducible results by ensuring complete denaturation of interfering proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases diagnostic reliability and sensitivity, reducing false positives and negatives, allowing for earlier and more accurate detection of Aspergillus infections, especially in challenging patient groups, and enables high-throughput screening with improved reproducibility.
Implementation Method 1
the sample is subjected to a denaturing step prior to contacting the sample with the antibody
Implementation Method 2
the sample is contacted with a first antibody binding specifically to said antigen and wherein any antigen bound to said first antibody is detected
Data Source
AI summary
The present invention relates to a method for diagnosing an Aspergillus infection in a patient, comprising the step detecting in a sample a proteinaceous antigen derived from mycelium of a pathogenic Aspergillus strain, wherein the sample is contacted with a first antibody binding specifically to said antigen and wherein any antigen bound to said first antibody is detected by way of a non-membrane based immunoassay, preferably selected from the group comprising an ELISA and a bead-based assay and a use of an antibody binding to a proteinaceous antigen derived from mycelium of a pathogenic Aspergillus strain for increasing the reliability of an immunoassay for the diagnosis of an Aspergillus infection in a patient as well as the method comprising the step coating a diagnostic device with a first antibody binding specifically to a proteinaceous antigen derived from mycelium of a pathogenic Aspergillus strain.